1 – 10 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer : A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels
(
- Contribution to journal › Article
- 2024
-
Mark
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer
(
- Contribution to journal › Article
-
Mark
European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update
(
- Contribution to journal › Scientific review
- 2023
-
Mark
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma : 2023 Update
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Swedish National Guidelines on Urothelial Carcinoma : 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma
(
- Contribution to journal › Article
-
Mark
Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review
(
- Contribution to journal › Scientific review
-
Mark
Immunohistochemical Assays for Bladder Cancer Molecular Subtyping : Optimizing Parsimony and Performance of Lund Taxonomy Classifiers
(
- Contribution to journal › Article
-
Mark
Adjuvant checkpoint inhibition after cystectomy–why, when, and for whom?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)
(
- Contribution to journal › Scientific review
-
Mark
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
(
- Contribution to journal › Article